In Vitro Efficacy Testing Services for Stomach Cancer

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Stomach Cancer. Our services offer comprehensive profiling of candidate compounds targeting key pathways such as PD-1/PD-L1, growth factor receptors, and apoptosis-related proteins that are highly relevant in gastric tumorigenesis. We enable mechanistic studies on cell proliferation, immune checkpoint modulation, and drug-target interactions. Our platforms allow detailed investigation of pathological processes including cancer cell viability, immune evasion, and intracellular signaling relevant to Stomach Cancer.

Our in vitro testing suite employs a diverse range of biochemical and cell-based assays, including viability, binding, and functional readouts, to evaluate compound activity and mechanism of action. We utilize advanced technologies such as flow cytometry, fluorescence-based assays, and biosensor platforms to deliver precise and reproducible results. These methods collectively support the identification, validation, and optimization of new therapeutic candidates for Stomach Cancer.

ATP assay: Measures cell viability and proliferation by quantifying cellular ATP levels, providing insight into cytotoxic or cytostatic effects of test compounds.

Biolayer interferometry assay: Assesses real-time biomolecular interactions, useful for characterizing binding kinetics between therapeutic agents and their targets.

CHO-K1 Chinese hamster ovary cells (CD274-overexpressing): Utilized to evaluate interactions with PD-L1 (CD274) and study immune checkpoint modulation.

CHO-K1 Chinese hamster ovary cells transfected with PDL1: Enables assessment of compound efficacy in modulating PD-L1-mediated cellular responses.

CHO-K1 Chinese hamster ovary cells transfected with PDL1/OKT3: Models immune synapse formation and tests immunotherapeutic candidate effects in a controlled system.

CHO-K1 Chinese hamster ovary cells transfected with human CD274/aAPC: Simulates antigen presentation and immune checkpoint interactions for functional evaluation.

Cells (effector) transfected with PD1: Used for immune cell functional assays, particularly in immune checkpoint and T cell activity studies.

Chemiluminescent assay: Sensitive detection of specific biomolecules or cellular events using luminescent signals, ideal for quantitative analyses.

Competitive binding assay: Determines the ability of compounds to displace ligands from target proteins, providing information on binding affinity.

Competitive binding assay (qPCR): Combines binding competition with quantitative PCR readout for highly sensitive detection of interaction dynamics.

Competitive binding assay (with CD274): Specifically assesses competition for PD-L1 binding, supporting immune checkpoint inhibitor development.

Dye assay (MTS): Measures cellular metabolic activity via colorimetric change, indicating cell viability or proliferation.

ELISA assay: Quantifies proteins, antibodies, or cytokines with high specificity, supporting biomarker and pharmacodynamic studies.

Flow cytometry assay: Enables multiparametric analysis of cell populations, including surface markers, viability, and functional status.

Fluorescence resonance energy transfer (FRET) assay: Detects molecular interactions and conformational changes based on energy transfer between fluorophores.

Fluorescent assay: Provides sensitive detection of cellular or molecular events using fluorescence intensity readouts.

Fluorescent polarization assay: Evaluates binding interactions and molecular size changes through polarization of emitted light.

Fluorescent-activated cell sorting (FACS) assay: Isolates and analyzes specific cell populations based on fluorescent markers for downstream applications.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Offers sensitive, high-throughput detection of molecular interactions or protein quantification.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT: Functional model for studying T cell activation and immune checkpoint signaling.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT/luciferase: Reports T cell activation via luminescence, enabling quantitative measurement of pathway modulation.

Jurkat human T-cell leukemia cells transfected with human PD1/NFAT/luciferase: Humanized cell system for assessing immune checkpoint inhibitor activity.

Luciferine/luciferase assay: Measures gene expression or ATP levels by detecting bioluminescence, supporting cell viability and reporter gene studies.

Poly(glutamine/tyrosine) peptide as substrate: Used in enzymatic assays to assess protease or kinase activity relevant to cancer signaling.

RNA assay: Quantifies gene expression changes in response to treatments, aiding mechanism-of-action studies.

Radioactivity assay: Measures radiolabeled compound uptake or interaction, providing sensitive quantitative data.

Saturation binding assay: Determines binding capacity and affinity of ligands for their targets, supporting drug-target interaction studies.

Surface plasmon resonance assay: Real-time, label-free analysis of biomolecular binding kinetics and affinities.

Tyrosine 4 peptide as substrate: Serves as a substrate in kinase assays to evaluate phosphorylation activity linked to signaling pathways in cancer.

We measure a suite of key pharmacological parameters that quantify compound potency, efficacy, and binding affinity. These metrics, including EC-50, IC-50, Kd, and Ki, provide critical insights into the therapeutic potential, selectivity, and safety margins of candidate drugs. Accurate parameter determination accelerates lead optimization and risk assessment in Stomach Cancer drug development.

EC-50: The concentration of a compound that produces 50% of its maximal effect, used to assess compound potency.

IC-50: The concentration required to inhibit a specific biological or biochemical function by 50%, indicating inhibitory activity and selectivity.

Kd: The dissociation constant representing the affinity between a drug and its target; lower Kd indicates stronger binding.

Ki: The inhibition constant, reflecting the binding affinity of an inhibitor for an enzyme or receptor, fundamental for comparing inhibitor strengths.

MEC: Minimum effective concentration, the lowest concentration at which a compound produces a measurable effect, important for dose selection.

MIC: Minimum inhibitory concentration, the lowest concentration that prevents visible growth of cells or organisms, relevant in cytotoxicity and antimicrobial testing.

pIC-50: The negative logarithm of the IC-50 value, providing a convenient scale for comparing compound potency.

Recommended In Vitro Efficacy Tests

Cd274 Molecule

The Cd274 molecule (PD-L1) plays a crucial role in immune evasion in stomach cancer. Testing its activity is vital for developing effective immunotherapies. Our service uses advanced methods—including FACS, flow cytometry, ELISA, surface plasmon resonance, biolayer interferometry, and PD1/NFAT reporter Jurkat cells—to assess key parameters such as MEC, Kd, IC-50, and EC-50, ensuring precise evaluation of drug candidates targeting PD-L1 in gastric cancer.

Claudin 18

Claudin 18 is frequently overexpressed in stomach cancer, making it a critical target for drug development. Claudin 18 testing is essential for evaluating candidate drugs’ binding affinity and inhibitory potency. Our service utilizes FACS, flow cytometry, surface plasmon resonance, biolayer interferometry, saturation binding, and ELISA assays to precisely measure key parameters such as dissociation constant (Kd) and half-maximal inhibitory concentration (IC-50), ensuring robust preclinical candidate assessment.

Dna Topoisomerase I

DNA Topoisomerase I is crucial in DNA replication and repair, making it a key target in stomach cancer drug development. Testing its inhibition helps identify effective therapeutic candidates. Our service employs a sensitive chemiluminescent assay to quantitatively assess enzyme activity. The main parameter measured is the Minimum Inhibitory Concentration (MIC), enabling precise evaluation of compound efficacy in inhibiting DNA Topoisomerase I relevant to stomach cancer treatment.

Erb-B2 Receptor Tyrosine Kinase 2

Erb-B2 Receptor Tyrosine Kinase 2 (HER2/ERBB2) plays a critical role in stomach cancer progression by promoting tumor cell growth and survival. Testing ERBB2 activity is vital for drug development and targeted therapy selection. Our service utilizes advanced methods—FACS, chemiluminescence, flow cytometry, FRET, SPR, biolayer interferometry, ELISA, and more—to assess drug efficacy. Key parameters measured include Ki, IC-50, Kd, MIC, and MEC, ensuring precise evaluation of candidate compounds.

Fibroblast Growth Factor Receptor 2

Fibroblast Growth Factor Receptor 2 (FGFR2) plays a critical role in stomach cancer by promoting tumor growth and survival. FGFR2 testing is essential for identifying and developing targeted therapies. Our service employs advanced methods—including FACS, HTRF, ELISA, flow cytometry, and ATP/luciferase assays—to assess FGFR2 activity and inhibitor efficacy. Key parameters measured (Ki, Kd, IC-50) enable precise evaluation of drug candidates’ potency and binding affinity, accelerating effective drug development.

Kinase Insert Domain Receptor

The Kinase Insert Domain Receptor (KDR/VEGFR-2) drives angiogenesis in stomach cancer, promoting tumor growth and metastasis. Accurate KDR testing is crucial for developing effective targeted therapies. Our service employs chemiluminescent, ATP, radioactivity, luciferin/luciferase, competitive binding (qPCR), RNA, and ELISA assays to assess drug efficacy. Key pharmacological parameters measured include pIC-50, MIC, and IC-50, enabling precise evaluation of candidate compounds’ inhibitory activities.

Mechanistic Target Of Rapamycin Kinase

Mechanistic Target Of Rapamycin (mTOR) kinase regulates cell growth and survival, playing a critical role in stomach cancer progression. mTOR kinase testing is essential for identifying pathway activation and guiding targeted therapy development. Key methods include immunohistochemistry, Western blotting, and kinase activity assays. Main parameters assessed are mTOR expression levels, phosphorylation status, and downstream signaling activity, enabling precise evaluation of drug efficacy in gastric cancer models.

Programmed Cell Death 1

The Programmed Cell Death 1 (PD-1) pathway is a key regulator of immune evasion in stomach cancer. PD-1 testing is crucial for developing targeted immunotherapies. We offer comprehensive assays—including FACS, chemiluminescence, flow cytometry, ELISA, surface plasmon resonance, and reporter cell lines (CHO-K1, Jurkat)—to evaluate PD-1/PD-L1 interactions. Key parameters measured include EC-50, IC-50, Kd, and MIC, supporting robust drug screening and candidate selection.

Signal Transducer And Activator Of Transcription 3

The Signal Transducer And Activator Of Transcription 3 (STAT3) plays a crucial role in stomach cancer by promoting tumor growth and survival. STAT3 testing is vital for drug development, enabling the identification and evaluation of STAT3-targeting compounds. Key assays include luciferin/luciferase, chemiluminescent, biolayer interferometry, and fluorescent polarization. Main parameters assessed are Kd (binding affinity), IC-50 (inhibitory concentration), and MIC (minimum inhibitory concentration), ensuring precise measurement of drug efficacy.